Connect Biopharma Holdings Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Connect Biopharma Holdings Limited (CNTB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Connect Biopharma Holdings Limited vs Its Competitors
- Growth: Connect Biopharma Holdings Limited generated 5,666.7% revenue growth year over year in Q2 2026, vs 12.0% for its tracked competitors combined.
- Profitability: Its -624.4% net margin compares with 7.2% for the peer group.
- Scale: Connect Biopharma Holdings Limited ranks #317 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Connect Biopharma Holdings Limited accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CNTB Sales vs. its Competitors, Q2 2026
Connect Biopharma Holdings Limited reported revenue growth of 5,666.67 % year on year in Q2 2026, above its competitors' combined revenue growth of 11.95 %.
With a net margin of -624.42 %, Connect Biopharma Holdings Limited reported lower profitability than its competitors (7.19 %).
Connect Biopharma Holdings Limited generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Connect Biopharma Holdings Limited vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Connect Biopharma Holdings Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Connect Biopharma Holdings Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Connect Biopharma Holdings Limited's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 5,666.7% for Connect Biopharma Holdings Limited. Connect Biopharma Holdings Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Connect Biopharma Holdings Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Connect Biopharma Holdings Limited | - | - | - | Yes |
| Competitors combined (100) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNTB Stock Performance relative to its Competitors
CNTB Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Abcellera Biologics Inc | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Connect Biopharma Holdings Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Connect Biopharma Holdings Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Connect Biopharma Holdings Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Connect Biopharma Holdings Limited | 61.61 | - |
| Eli Lilly And Company | 1,027,620.95 | 79,665.80 |
| Johnson and Johnson | 631,156.27 | 97,929.00 |
| Beone Medicines Ltd | 540,078.69 | 6,128.24 |
| Abbvie Inc | 460,336.03 | 64,386.00 |
| Merck and Co Inc | 355,210.70 | 66,569.00 |
| SUBTOTAL | 4,977,665.21 | 837,914.75 |
Sign in to see all competitors of Connect Biopharma Holdings Limited.
Sources: Connect Biopharma Holdings Limited's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Connect Biopharma Holdings Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Connect Biopharma Holdings Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Connect Biopharma Holdings Limited | Treatment of Respiratory Diseases 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Connect Biopharma Holdings Limited.
Connect Biopharma Holdings Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Connect Biopharma Holdings Limited | 62 | - | -1,077,984 |
| Eli Lilly And Company | 1,027,621 | 1,593,316 | 534,224 |
| Johnson and Johnson | 631,156 | 695,518 | 149,411 |
| Beone Medicines Ltd | 540,079 | 510,686 | 54,642 |
| Abbvie Inc | 460,336 | 1,129,579 | 110,807 |
| Merck and Co Inc | 355,211 | 887,587 | 42,267 |
| PEERS TOTAL | 4,977,604 | 901,005 | 131,651 |
Sign in to see all peers for Connect Biopharma Holdings Limited.
Connect Biopharma Holdings Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Connect Biopharma Holdings Limited.
Connect Biopharma Holdings Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Connect Biopharma Holdings Limited's industry classification, broader than the peer set above. Market cap in millions of $.Connect Biopharma Holdings Limited ranks #317 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 816, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,029,931 | 19.10 % |
| 2 | Johnson and Johnson | 643,198 | 11.93 % |
| 3 | Beone Medicines Ltd | 553,175 | 10.26 % |
| 4 | Abbvie Inc | 461,540 | 8.56 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 317 | Connect Biopharma Holdings Limited | 69 | 0.00 % |
Market cap and industry share for the rest of Connect Biopharma Holdings Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-01.
Connect Biopharma Holdings Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 312 | Gain Therapeutics inc | 72 | -5.08 % |
| 313 | Renovorx Inc | 72 | 19.69 % |
| 314 | Maia Biotechnology Inc | 72 | -23.38 % |
| 315 | Os Therapies Incorporated | 70 | -18.37 % |
| 316 | Spero Therapeutics Inc | 1,234 | 12.3% |
| 317 | Connect Biopharma Holdings Limited | 69 | -26.99 % |
| 318 | Fortress Biotech Inc | 1,234 | 12.3% |
| 319 | Xbiotech Inc | 1,234 | 12.3% |
| 320 | Pliant Therapeutics Inc | 1,234 | 12.3% |
| 321 | Cingulate Inc | 1,234 | 12.3% |
| 322 | Skye Bioscience Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Connect Biopharma Holdings Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-01. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Connect Biopharma Holdings Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 6.9x | 4.5x | +2.4x |
| Return on Equity | -333.30 % | industry aggregate | -350.55 % |
| Return on Invested Capital | -59.94 % | -2.85 % (avg) | -57.09 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Connect Biopharma Holdings Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -18.16 % | -33.80 % | -22.52 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Connect Biopharma Holdings Limited's BCG Growth-Share Matrix
Relative market share (vs Connect Biopharma Holdings Limited's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Connect Biopharma Holdings Limited falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Connect Biopharma Holdings Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 816 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Connect Biopharma Holdings Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Connect Biopharma Holdings Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Connect Biopharma Holdings Limited's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Connect Biopharma Holdings Limited falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Connect Biopharma Holdings Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 350.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (36.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Connect Biopharma Holdings Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Connect Biopharma Holdings Limited | 2.56 | 3.55 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Connect Biopharma Holdings Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Connect Biopharma Holdings Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Connect Biopharma Holdings Limited | Q2 2026 | +5,666.7 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.2 % | -11.8 % |
Sign in to see all peers for Connect Biopharma Holdings Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Connect Biopharma Holdings Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Connect Biopharma Holdings Limited | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Connect Biopharma Holdings Limited.
Connect Biopharma Holdings Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Connect Biopharma Holdings Limited | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Connect Biopharma Holdings Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Connect Biopharma Holdings Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Connect Biopharma Holdings Limited | - | - |
| Eli Lilly And Company | 38.60 | 12.90 |
| Johnson and Johnson | 29.94 | 6.45 |
| Beone Medicines Ltd | 815.39 | 88.13 |
| Abbvie Inc | 73.43 | 7.15 |
| Merck and Co Inc | 115.98 | 5.34 |
| PEERS AVERAGE | 40.68 | 5.94 |
Sign in to see all peers for Connect Biopharma Holdings Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.